CER 002

Drug Profile

CER 002

Alternative Names: CER-002; NC-2400

Latest Information Update: 15 Sep 2015

Price : $50

At a glance

  • Originator Nippon Chemiphar
  • Developer Cerenis Therapeutics
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dyslipidaemias
  • No development reported Atherosclerosis

Most Recent Events

  • 15 Sep 2015 CER 002 is still in phase I clinical development for Dyslipidaemias in USA
  • 15 May 2008 Phase-I clinical trials in Atherosclerosis in USA (PO)
  • 15 May 2008 Cerenis Therapeutics completes a phase I trial in healthy volunteers for application in Cardiovascular disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top